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Abstract 
Background: Neuropsychiatric symptoms (NPS), such as depression, apathy, agitation and 
psychotic symptoms, are common in mild cognitive impairment (MCI) and dementia in 
Alzheimer’s disease (AD). Subgroups of NPS have been reported. Yet the relationship of NPS 
and their subgroups to different stages of cognitive impairment is unclear. Most previous 
studies are based on small sample sizes and show conflicting results. We sought to examine the 
frequency of NPS and their subgroups in MCI and different stages of dementia in AD.  
 
Method: This was a cross-sectional study using data from a Norwegian national registry of 
memory clinics. From a total sample of 4571 patients, we included those with MCI or AD (MCI 
817, mild AD 883, moderate-severe-AD 441). To compare variables across groups ANOVA or 
χ2-test was applied. We used factor analysis of Neuropsychiatric Inventory Questionnaire (NPI-
Q) items to identify subgroups of NPS. 
 
Results: The frequency of any NPS was 87.2% (AD 91.2%, MCI 79.5%; p<0.001) and 
increased with increasing severity of cognitive decline. The most frequent NPS in MCI was 
depression. Apathy was the most frequent NPS in AD across different stages of severity. The 
factor analysis identified three subgroups in MCI and mild AD, and a fourth one in moderate-
severe AD. We labelled the subgroups “depression”, “agitation”, “psychosis” and “elation”.  
 
Conclusions: The frequency of NPS is high in MCI and AD and increases with the severity of 
cognitive decline. The subgroups of NPS were relatively consistent from MCI to moderate-
severe AD. The subgroup elation appeared only in moderate-severe AD.  
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Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and 
different stages of dementia in Alzheimer’s disease 
 
Introduction 
Alongside cognitive symptoms, the majority of patients with dementia in Alzheimer’s disease 
(AD) or mild cognitive impairment (MCI) show neuropsychiatric symptoms (NPS) (Lyketsos 
et al., 2011). Common NPS include among others depression, apathy, agitation, delusions, and 
hallucinations. Individual NPS tend to form discernible subgroups (Van Der Linde et al., 2014). 
There is evidence of a high frequency of NPS in MCI (Apostolova and Cummings, 2008) and 
AD (Lyketsos et al., 2011), yet it is reported to vary considerably. A review (Cerejeira et al., 
2012) reported frequencies of NPS across studies in MCI (up to 85%) and dementia (up to 
98%). Higher rates of NPS in clinical than in community based settings were found in both 
dementia (91-96% vs 56-98%) and MCI (75 vs. 43%) (Apostolova and Cummings, 2008). A 
meta-analysis of NPS in AD (Zhao et al., 2016) found a wide range for the frequency of 
individual NPS in AD across studies, for instance for apathy (19 – 88%), delusions (9- 59%), 
hallucinations (6 – 41%) or aberrant motor behavior (0.8 – 70%). In a meta-regression, 
however, they found an overall heterogenous correlation of different factors to the frequency 
of NPS in AD, such as study setting or evaluation method. 
 
An increasing frequency of NPS along increasing severity of AD is described (Lopez et al., 
2003), but conflicting results were found. Some authors (Starr and Lonie, 2007) reported a weak 
relationship between NPS and cognitive performance in AD, whereas others failed to detect an 
association between NPS and cognitive performance, regarding cognitive symptoms and NPS 
as independent dimensions of dementia (Lam et al., 2006). Some individual NPS seem to be 
associated with the level of cognitive decline: depression is reported to predominate in MCI 
(Ismail et al., 2017), apathy is described as most common and stable throughout different stages 
of AD and psychotic symptoms are found to be highly prevalent in more severe stages of AD 
(Craig et al., 2005).  
 
The most consistently reported subgroups in studies with factor analyses are depression, 
psychosis, and hyperactivity (Van Der Linde et al., 2014), though number and composition of 
subgroups vary across studies. Most studies found between three and five subgroups (Cerejeira 
et al., 2012). Some individual NPS in these subgroups, such as depression, hallucinations, and 
delusions, appear as stable across studies. Other NPS, however, such as motor disturbance, 
night time behavior or anxiety, seem to be less specific and were included in different subgroups 
or overlapped across them. Motor disturbance for instance co-occurred with depression, 
anxiety, delusions, hallucinations, and night-time behaviour in a subgroup labelled 
“mood/psychosis/psychomotor agitation” in one study (Zuidema et al., 2007), in another study 
(Aalten et al., 2008), however, with agitation, euphoria, disinhibition and irritability in a 
subgroup labelled “hyperactivity”.   
 
Most studies into the frequency of NPS in MCI and dementia analyzed samples with fewer than 
500 subjects. They vary, however, in setting, rating tools, and included patients with dementia 
of varying aetiologies and severity (Cerejeira et al., 2012). Only few studies included MCI and 
AD in one setting. Unlike ours, they were community based (Okura et al., 2010; Lyketsos et 
al., 2002) or based on a small sample for MCI (n=28) and AD (124) (Hwang et al., 2004). We 
found only two larger studies (Aalten et al., 2008; Zuidema et al., 2007) with sample sizes 
between 1000 and 2000 subjects that analyzed the subgroups of NPS in different stages of 
dementia. These two studies, however, diverged in several aspects. They included outpatients 
from multiple centers (Aalten et al., 2008) or nursing-home patients (Zuidema et al., 2007) and 
described diverging frequencies for depression (37% vs 20%), apathy (56% vs 34%) and 
delusions (19% vs 14%) as well as diverging solutions for their NPS subgroups. One study 
(Aalten et al., 2008) revealed the subgroups hyperactivity, affective, apathy, psychosis, and a 
subgroup with euphoria and motor disturbance, the other one (Zuidema et al., 2007) revealed 
the subgroups agitation/aggression, psychosis, depression, psychomotor agitation and apathy. 
In addition, their conclusions on NPS subgroups across different stages of dementia varied. One 
study concluded that the profile did not vary with severity (Zuidema et al., 2007), whereas the 
other one (Aalten et al., 2008) found some differences, since a subgroup with euphoria and 
motor disturbance appeared only in severe dementia, while the psychosis subgroup disappeared. 
Neither study included patients with MCI.  
 
The aim of this cross-sectional study was to describe the frequency of NPS and identify their 
subgroups in a large cohort of subjects with MCI and AD of varying severity. Our study differs 
from previous studies particularly by the size of its clinical sample with more than 2000 enrolled 
subjects. We thus could study a group of robustly diagnosed AD patients larger than in any 
comparable study we know of. To date, only few studies into the frequency and the subgroups 
of NPS included subjects with MCI and AD of varying severity in one setting. On the 
background of the mentioned inconsistencies, the varying results across studies and especially 
the mostly small sample sizes of previous studies, we expect to contribute valuable findings to 
the literature. 
 
Material and methods 
Material 
This is a cross-sectional registry-based clinical study assessing frequency and subgroups of 
NPS in subjects with MCI and different stages of AD (mild, moderate-severe). The study is 
based on the Norwegian Registry of persons with cognitive symptoms (NorCog), which to date 
includes 4571 subjects. The registry was appointed the status of a combined national research 
and quality registry in 2013 and is run by the Norwegian National Advisory Unit on Ageing 
and Health. Inclusion and collection of data is based on patients' and relatives' informed consent 
in writing. Throughout Norway, 26 memory clinics participate in collecting data. The registry 
is approved by the Norwegian Data Protection Authority and the Regional Committee for 
Medical and Health Research Ethics (REC 2016/592). In this study, we included subjects with 
MCI or AD for whom Neuropsychiatric Inventory-Questionnaire (NPI-Q) score (Kaufer et al., 
2000) and Mini Mental State Examination (MMSE) (Folstein et al., 1975) were available. 
 
Examinations and diagnoses 
Three groups of subjects were included: MCI; mild, and moderate-severe AD. The subjects 
were examined following a common protocol. Diagnostic assessment consisted of medical 
history, standard assessment scales, physical examination, blood samples, and structural 
imaging (computerized tomography or magnetic resonance imaging). In some subjects, 18-
fludeoxyglucose positron emission tomography (18-FDG PET) or single photon emission 
computed tomography (SPECT) and cerebrospinal fluid (CSF) analysis of beta-amyloid, total 
tau and phosphorylated tau protein were used to aid in the diagnosis. In these subjects CSF was 
examined for cells, protein and glucose. Protein electrophoresis and analysis of antibodies for 
Borrelia Burgdorferi were also performed.   
 
Clinical assessment 
The physical examination included measurement of height, weight and blood pressure, a 
preliminary neurological examination with emphasis on signs of cortical damage such as 
aphasia or anopsia and other signs such as hemiparesis, sensory loss or ataxia. The psychiatric 
evaluation was conducted with emphasis on cognitive symptoms such as memory impairment, 
especially short term memory, loss of orientation and concentration.   
 
Neuropsychiatric and cognitive assessment 
Neuropsychiatric symptoms were examined by the NPI-Q. Cognitive tests included tests from 
the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) (Morris et al., 1989), 
such as the MMSE, verbal fluency test (Isaacs and Kennie, 1973) and 10 word list (Atkinson 
and Shiffrin, 1971). Further cognitive tests were the clock drawing test (CDT) (Shulman, 2000), 
and the trail making test a and b (TMT A and B) (Reitan, 1955). 
 
The NPI-Q is an informant based questionnaire, providing a brief assessment of 
neuropsychiatric symptomatology in clinical practice settings. It is based on the 
Neuropsychiatric inventory (NPI) (Cummings et al., 1994). The NPI-Q is widely used and 
validated (Kaufer et al., 2000). The questionnaire includes 12 neuropsychiatric items: delusions, 
hallucinations, agitation/aggression, depression, anxiety, elation/euphoria, apathy/indifference, 
disinhibition, irritability/lability, motor disturbance, night time behaviors, and appetite/eating. 
For each of the 12 NPI-Q items the interview provides an initial screening question with 
response options "Yes" (present) and "No" (absent).  If the response is "Yes", the informant 
rates the severity of the symptoms on a 3-point-scale (mild, moderate, severe). NPS were 
considered as present if at least one NPI-Q item had a score > 0. The Norwegian version of the 
NPI-Q has been validated (Rogne and Ulstein, 2012). 
 
The Mini-Mental State Examination (MMSE) (Folstein et al., 1975) assesses global cognitive 
functioning. It provides 20 items concerning orientation, registration and recall, attention, 
language, following commands, and ﬁgure copying. The maximum score is 30. A lower score 
indicates worse cognitive functioning and a score <24 has been considered to reflect cognitive 
impairment (O'connor et al., 1989). The Norwegian version (MMS-NR) has been validated 
(Engedal et al., 1988). 
 
The verbal fluency test (Isaacs and Kennie, 1973) measures impairment in verbal production, 
semantic memory, and language. Subjects are asked to name as many animals as possible in 1 
minute. The score is the total number of different animals named. 
 
The 10 word list from the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) battery (Atkinson and Shiffrin, 1971) evaluates the ability to remember newly 
learned information. A list of 10 words is presented in 3 trials in random order and the subject 
tries to recall all 10. The scoring represents the total number of correct words learned. The 
maximum number of correct responses is 30 for the 3 trials. 
 
The Clock Drawing Test (CDT) (Shulman, 2000) assesses visuoconstructive abilities. The 
subjects were presented with a circle on a piece of paper and asked to draw the face of a clock, 
reading “10 after 11”.  We used the scoring method as described by Shulman (0–5, where 5 is 
best). 
 
The trail making test (parts A and B) (Reitan, 1955) evaluates attention, executive function and 
processing speed. In part A (TMT-A) the subject is asked to draw a line between dots in 
increasing order (1–25). In part B (TMT-B) the ability to shift between multiple tasks is tested. 
In addition to the task of part A, the subject is asked to alternate between numbers and letters. 
Performance is scored from 0 to 4 (0=cannot complete, 1=slower than -2 standard deviations 
of the norms, 2=between -1 and -2 standard deviations, and 3=better than -1 standard deviation). 
 
The subjects’ functional status in activities of daily living (ADL) was assessed by Lawton and 
Brody’s scales for ADL (Lawton and Brody, 1969): they measure personal ADL (P-ADL) and 
instrumental ADL (I-ADL). The P-ADL consists of 6 items, which can be scored from 1 to 5, 
giving a minimum score of 6 and a maximum score of 30. The I-ADL scale includes 8 items, 
which can be scored from 1 to 5. The items of the I-ADL have different maximum scores, 
resulting in a minimum score of 8 and a maximum score of 31. On both scales, higher scores 
indicate greater dependence in the performance of the ADL.  
 
In all participating clinics the Norwegian versions of the MMSE, verbal fluency test, 10 word 
list, CDT, TMT A and B, and Lawton and Brody’s scales were used in standardized interviews 
according to a common protocol, which was used in previous studies (Persson et al., 2015; 
Tangen et al., 2014).  
 
A diagnosis of MCI was made in accordance with the Winblad criteria (Winblad et al., 2004): 
1) the person is neither cognitively normal nor demented; 2) there is evidence of cognitive 
deterioration shown by either objectively measured decline over time and/or subjective report 
of decline by self and/or informant in conjunction with objective cognitive deficits; and 3) 
activities of daily living are preserved and complex instrumental functions are either intact or 
minimally impaired (Winblad et al., 2004).  
 
A diagnosis of AD was made in accordance with the ICD-10 criteria (World Health, 1992): (a) 
Presence of a dementia. (b) Insidious onset with slow deterioration. (c) Absence of clinical 
evidence, or findings from special investigations, to suggest that the mental state may be due to 
other systemic or brain disease. (d) Absence of a sudden, apoplectic onset, or of neurological 
signs of focal damage.  
 
Meetings were held annually among collaborating clinicians to establish and retain 
harmonized procedures and diagnostic inter-rater reliability. 
 
Dementia stages in AD 
We used Mini Mental State Examination (MMSE) to define categories of dementia severity, 
as has been done previously (Folstein et al., 1975; Aalten et al., 2008; Lopez et al., 2003), as 
mild, moderate and severe (MMSE scores >=20; 19 to 10; <10). The moderate and severe 
groups were combined into one moderate-severe group, since the severe group consisted of 
only 12 patients.  
 
Statistical analysis 
Demographic and clinical patient characteristics were described as means and standard 
deviations (SD) or frequencies and percentages, as appropriate. ANOVA was applied to 
compare continuous variables across patient groups. χ2-test was used for comparison of 
categorical variables across patient groups.  
 
To identify subgroups of NPS, factor analysis of NPI-Q items was performed with principal 
component extraction method and varimax rotation. An oblique rotation was considered as well 
but due to weak correlations among the factors a varimax method was chosen. The number of 
components was identified by the Kaiser’s criterion of eigenvalues equal to or higher than 1. 
Cronbach’s alpha was calculated to assess the consistency of the factors. We adhered to the 
following cut-offs (Hinton, 2004): high (α>0.75), moderate (0.5<α<0.75), low consistency 
(α<0.5). 
 
All analyses were performed in SPSS v 22. Results with p-values below 0.05 were considered 
statistically significant. 
 
Results  
The total sample consisted of 4571 subjects, with MCI or AD in 2141 subjects (43.2% male). 
Of these 817 had MCI, and 1324 AD (883 mild, 429 moderate and 12 severe). A recruitment 
chart is given in Figure 1. The clinical and demographic characteristics of the groups are shown 
in Table 1.  
 
At least one NPS was found in 87.2% of the patients (AD 91.2%, MCI 79.5%). The NPS 
frequency and the NPI-Q total sum score increased significantly from MCI to mild AD 
(p<0.001, χ2-test) and increased slightly, though non-significantly further from mild to 
moderate-severe AD, Figure 2. The number of patients with two or more NPS was significantly 
higher in patients with AD than in those with MCI (AD 79.9%, MCI 65.3%; p<0.001, χ2-test). 
 
The most common NPS in MCI was depression, followed by apathy. In AD, apathy was the 
most common NPS and was significantly more common than in MCI (p<0.001, χ2-test). The 
frequencies of delusions and hallucinations increased with increasing severity of cognitive 
decline (p<0.001, χ2-test). Results for all individual NPS across different stages from MCI to 
moderate-severe AD are shown in Figure 3. 
 
Factor analysis with principal component analysis 
The results of the factor analysis of the entire data set are shown in Table 2. Three factors based 
on NPI-Q items were extracted, explaining 48.6% of the variance. Factor 1 contained the items 
depression, anxiety, disturbances in appetite, apathy, motor disturbance, night time disturbance 
(30.1% of variance explained), factor 2 contained the items euphoria, disinhibition, irritability, 
and agitation (9.4% of variance explained), and factor 3 contained the items hallucinations and 
delusions (9.1% of variance explained). The consistency of the factors was considered moderate 
with Cronbach’s alpha of 0.68 for factor 1, 0.64 for factor 2 and 0.58 for factor 3. We labelled 
factor 1 the depression subgroup, factor 2 agitation subgroup and factor 3 psychosis subgroup. 
 
The factor analysis stratified for the groups MCI to moderate-severe AD (data not shown) 
showed an unchanged factor composition for MCI and mild AD. The consistency of the 
subgroups was moderate for depression (Cronbach’s alpha in MCI 0.70, in mild AD 0.64), 
agitation (Cronbach’s alpha in MCI 0.67, in mild AD 0.65) and psychosis (Cronbach’s alpha in 
MCI 0.53, in mild AD 0.52). While in moderate-severe AD the factor composition of the 
subgroups depression and agitation was slightly different, the consistency of both subgroups 
remained nearly unchanged with a moderate consistency for depression (Cronbach’s alpha 
0.65) and agitation (Cronbach’s alpha 0.69). The depression subgroup contained depression 
and anxiety; the agitation subgroup still contained agitation, disinhibition, irritability, and in 
addition disturbances in night time behavior, appetite and eating, and apathy, while it no longer 
contained euphoria. The psychosis subgroup showed an unchanged composition and a now 
moderate consistency (Cronbach’s alpha 0.67). An additional factor appeared, containing 
euphoria and motor disturbance and was labelled elation subgroup. Its consistency, however, 
was low (Cronbach’s Alpha 0.24).  
 
Discussion 
In this cohort of more than 2000 subjects with MCI or AD of varying severity, the frequency 
of NPS was high in all groups. It increased significantly from MCI to mild AD with a slight 
further, yet non-significant increase in moderate-severe AD. The following neuropsychiatric 
subgroups were identified: depression, agitation, psychosis and elation. Across different levels 
of cognitive decline from MCI to moderate-severe AD, the subgroups depression, psychosis 
and agitation remained relatively stable, whereas the elation subgroup appeared only in 
moderate-severe AD. Taken together, the available evidence suggests that the pathology of AD 
contributes to NPS in AD, although it should be noted that not all MCI patients will develop 
AD or other types of dementia. 
 
 
Our study supports findings that indicate a high frequency of NPS in both MCI (Apostolova 
and Cummings, 2008) and AD (Lyketsos et al., 2011). We could show that the frequency of 
NPS was higher in AD than in MCI. This is generally in line with results of community based 
studies (Okura et al., 2010; Lyketsos et al., 2002). These two studies, however, analyzed smaller 
samples than we did (n=856, n=682) and described frequencies of NPS for MCI (44%, 43%) 
and AD (57%, 75%) that were considerably lower than ours. Moreover, they included dementia 
of varying aetiologies (Okura et al., 2010; Lyketsos et al., 2002). Where different stages of 
dementia were analyzed (Okura et al., 2010), the results were partly different from ours, as the 
frequency of NPS slightly decreased in severe dementia, whereas it slightly increased in this 
stage in our study. Another clinical study (Hwang et al., 2004) found frequencies of NPS in 
MCI (75%) and mild AD (89%) that were comparable to ours, however in a sample (n=202) 
much smaller than ours. They found a considerably lower frequency of NPS (12%) in a 
cognitively unimpaired control group (n=50). Higher frequencies of NPS in clinic versus 
community based settings have been described (Cerejeira et al., 2012; Apostolova and 
Cummings, 2008) and may originate from a referral bias, since patients in clinical treatment 
may be more impaired than those in a community setting.  
 
The number of subjects in different levels of dementia severity in our study differed from that 
in previous studies. The two larger studies (Zuidema et al., 2007; Aalten et al., 2008), that 
performed a factor analysis in different stages of dementia, analyzed a considerably higher 
number of moderate to severely impaired patients than we did (n=1378, n=1793) and a 
comparable (n=1015) (Aalten et al., 2008) or much smaller (n=59) (Zuidema et al., 2007) 
number of subjects with mild dementia. They did so, however, regardless of dementia subtype 
and the proportion of subjects with AD is unclear. A clinical study (Hwang et al., 2004), that 
assessed the frequency of NPS in MCI and AD, analyzed considerably fewer subjects in both 
MCI (n=28) and mild AD (n=124) and did not include moderate or severe stages of AD.  
 
The most frequent NPS in our MCI group was depression (49%, Figure 3). A high frequency 
of depression in MCI (27%) has been reported previously in a population based study  (Geda 
et al., 2008). A meta-analysis (Ismail et al., 2017) reported the pooled prevalence of depression 
in patients with MCI (32%), which varies across clinic (40%) and community based settings 
(25%). The interaction of depression and MCI is widely discussed and depression seems to be 
associated with a higher risk of conversion to dementia (Mourao et al., 2016). It is, however, 
unclear if depression in MCI is an early manifestation of neurodegeneration or a reaction to the 
experience of cognitive impairment. Depression and MCI can have overlapping symptoms 
(Ismail et al., 2017). Depression was the second most frequent NPS in mild (51%) and 
moderate-severe AD (53%) (Figure 3). The interaction of depression and dementia is complex: 
depression can appear as “pseudodementia” (i.e. reversible cognitive impairment induced by 
depression). On the other hand, depression may also be a symptom of the underlying AD 
pathology. A clinicopathological study describes depression as independent of neuritic plaques 
and fibrilles in MCI and mild AD (Mccutcheon et al., 2016). The most frequent NPS in our AD 
groups was apathy (58%), which was significantly more frequent than in MCI (39%). Its 
frequency in moderate-severe AD (58%) was almost as it was in mild AD (59%) (Figure 3). 
Overall, our frequencies for depression and apathy in AD concur with the findings of a recent 
meta-analysis (Zhao et al., 2016), reporting frequencies of apathy (49%) and depression (42%). 
We found delusions and hallucinations were significantly more frequent in moderate-severe 
AD than in mild AD and MCI (Figure 3). Some authors (Lyketsos et al., 2001), though, describe 
the increase of hallucinations as weak, whereas in our study their frequency was almost twice 
as high in moderate severe AD than it was in MCI. 
 
The subgroups of NPS we found are both clinically plausible and overall in line with previous 
findings (Van Der Linde et al., 2014). Across studies, however, rating methods for NPS 
differed. Most studies used the NPI (Cerejeira et al., 2012), but those using other instruments 
(e. g.  Behavioral Pathology in Alzheimer’s Disease Scale, Neurobehavioral Rating Scale, 
Behaviour Rating Scale for Dementia) found comparable results. We found two studies, 
comparable to ours, that performed a factor-analysis of NPI-Q items. One of these (Johnson et 
al., 2011) reported a factor solution, that was partly comparable to ours, albeit some divergent 
NPS were included into their subgroups, labelled “mood” (anxiety, apathy, and depression), 
“psychosis” (irritability, delusions, hallucinations, agitation) and “frontal symptoms” (euphoria 
and disinhibition). However, they analyzed and compared dementia with varying aetiologies 
such as AD, Vascular dementia (VaD), and dementia with Lewy Bodies (DLB). Their AD 
group was considerably larger than ours (n=2474). Another study (Travis Seidl and Massman, 
2016) suggested a factor solution with only two subgroups, labelled Negative/Oppositional 
(agitation, irritability, apathy, depression, disinhibition, and delusions) and 
Anxiety/Restlessness (nighttime behavior, anxiety, hallucinations, and appetite). Here (Travis 
Seidl and Massman, 2016), however, the items motor disturbance  and euphoria were excluded 
from the factor analysis, and the AD sample (n=256) was considerably smaller than ours. 
Neither of these analyzed the subgroups in MCI or different stages of dementia. 
 
Minor differences in the subgroups of NPS exist between our study and other studies that used 
the NPI. One study (Lyketsos et al., 2001) described a psychosis subgroup similar to ours, and 
an affective subgroup (depression, irritability, anxiety, euphoria), that partly resembled our 
depressive subgroup, but included irritability and euphoria, which we included into the agitation 
subgroup. That study, though, used latent class analysis, was community based and examined 
a much smaller sample of AD patients (n=198). In another study (Aalten et al., 2003), motor 
disturbances have been included in the agitation subgroup, which in our analysis have been 
included in the depression subgroup. That study, however, analyzed a smaller sample and their 
patients met criteria for varying types of mostly mild dementia, such as AD, VaD, mixed AD 
and VaD, frontal dementia (FTLD), dementia in Parkinson’s disease (PDD) and DLB. 
 
The stratified factor analysis for different stages form MCI to moderate-severe AD showed 
some changes in both the composition and the number of NPS subgroups.  In our MCI and mild 
AD groups, apathy was included in the depressive subgroup. Apathy and depression can overlap 
clinically, and there is an ongoing discussion about the status of apathy as a syndrome distinct 
from depression (Mortby et al., 2012). The definitions of depression and apathy often overlap 
(Cummings et al., 2015).  Apathy and depression may or may not occur together. In moderate-
severe AD apathy was included in the agitation subgroup, which has been reported previously 
(Archer et al., 2007). Patients with severe AD often show shifting symptoms, especially 
between agitation and apathy. Some authors (Archer et al., 2007) speculate that co-occurrence 
of apathy and agitation may be a sign of shared disturbances in the frontal lobe. In our moderate-
severe AD group, an additional subgroup was identified, which we labelled elation. Its 
consistency, however, was low (Cronbach’s alpha 0.24) and this finding should be confirmed 
or rejected in further studies. 
 
In the few studies that applied factor analyses of NPS in different stages of cognitive decline, 
we found no agreed upon suggestions for the stability of a factor across different levels of 
cognitive decline. In different stages of cognitive decline all of our subgroups maintained two 
or more NPS, which may be looked upon as core symptoms and which we labelled our 
subgroups after. These NPS were described as relatively specific before (Van Der Linde et al., 
2014). At any stage of cognitive decline our subgroups were in line with generally suggested 
compositions of NPS subgroups (Van Der Linde et al., 2014). Therefore and because of their 
almost invariant consistency we conclude that they are stable across different levels of cognitive 
decline. Since the elation subgroup appeared only in moderate-severe AD, we regard it as stage 
dependent, which is in line with the findings of a previous study (Aalten et al., 2008).   
 
There is evidence of a generally high prevalence of NPS across other neurodegenerative 
diseases, although it varies across diagnoses with reported rates for Huntington’s disease (HD) 
(98%) (Paulsen et al., 2001), DLB (95%) (Bjoerke-Bertheussen et al., 2012), VaD (70%) 
(D'onofrio et al., 2012), and Parkinson’s Disease (PD) (60%) (Aarsland et al., 1999b). A recent 
review (Cerejeira et al., 2012) indicates varying predominant NPS across dementias of different 
aetiologies, such as depression and anxiety in VaD, psychotic symptoms in DLB, and 
disinhibition and apathy in FTLD. A study (Aarsland et al., 2007) into NPS in PDD found 
depression as the most common NPS in this diagnosis. In HD, depression and agitation were 
reported as the most frequent NPS (Paulsen et al., 2001). Although these findings may suggest 
a heterogenous profile of individual NPS across varying types of dementia, there is some 
evidence for an overall comparable constellation of subgroups of NPS in AD, PDD, VaD and 
DLB (Johnson et al., 2011). 
 
We see some limitations to our study design. We selected subjects with MCI and AD in a 
clinical setting, and the results may be subject to referral bias and thus not generalizable to the 
general population. A cross-sectional design fails to detect fluctuations and trajectory of NPS, 
so that the severity-related associations may not be entirely accurate. We did not apply 
histopathological examinations for the diagnosis of AD, misdiagnosis thus is possible. We did 
not adjust for medication, which can influence NPS. The NPI-Q, though validated (Kaufer et 
al., 2000) and often used, has shortcomings, as it provides informant-based data, so we may be 
prone to overreliance on proxy report. However, studies that used instruments other than the 
NPI-Q yielded overall comparable results. Analyses conducted at the participating centres may 
be underrepresented in the NorCog registry. Diagnostic routine may vary slightly across the 
participating centers: all of them collected blood samples; in some cases computered 
tomography and MRI of the brain were conducted by the general practitioner, nevertheless in 
accordance to the research protocol; few analyzed CSF and these data were not available.   
 
Some of our findings may be influenced or explained by the specific questions in the NPI-Q. A 
part of the question about hallucinations (“Does the patient have hallucinations such as false 
visions or voices”) could have been affected by a part of the question about delusions (“Does 
the patient have false beliefs?”) or vice versa. These items may be difficult to separate for an 
informant not trained in psychiatry. The slightly lower Cronbach’s alpha in the psychosis 
subgroup may possibly be explained by this. The inclusion of motor disturbance in the 
depression subgroup may be explained by the wording in the NPI-Q (“Does the patient engage 
in repetitive activities such as pacing around the house, handling buttons, wrapping string, or 
doing other things repeatedly?”). Motor disturbance, however, is reported to be a key symptom 
in severe depression, that increases with age (Parker et al., 2001). In the NPI-Q, there are no 
guidelines to distinguish the items apathy (“Does the patient seem less interested in his/her 
usual activities or in the activities and plans of others”) and depression (“Does the patient seem 
sad or say that he /she is depressed?”), which may contribute to the sometimes difficult 
disentanglement of these items. Since we did not include a healthy control group we could not 
directly compare the frequencies of neuropsychiatric symptoms in AD and MCI with the normal 
population. However, previous studies, including a Norwegian study (Aarsland et al., 1999a), 
have reported much lower frequencies of NPS in cognitively healthy controls, supporting the 
conclusion that neuropsychiatrjc symptoms are associated with the underlying disease. 
 
Strengths of this study include the inclusion of a large sample size assessed with a common 
standardized protocol and the inclusion of subjects across the full spectrum from MCI to severe 
AD, which allows us to study different stages of cognitive decline, although the number of 
patients with severe AD was low. Since frequency and severity of NPS tend to increase with 
disease progression this will inevitably influence the findings. 
 
Taken together, in our study the frequency of NPS was high in both MCI and AD. It increased 
only slightly with the severity of AD. Although the subgroups depression and agitation showed 
changes in their composition, we regard them as stable across different levels of cognitive 
decline, since they maintained at least two NPS. Our psychosis subgroup was invariant across 
different levels of cognitive decline, while the elation subgroup was dependent on moderate-
severe AD. The observed subgroups can thus be considered reflections of non-cognitive 
syndromes that occur alongside cognitive disturbances in MCI and AD, regardless of level of 
cognitive decline. The relevance of the subgroup elation can be debated, since its consistency 
was low.  
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